Evidence map›Paper›PMID 41639692›Full record

ReviewJournal of translational medicine2026

De novo protein design: a transformative frontier in clinical protein applications.

Jie Gao, Zaiyong Zheng, Xueting Yu, Yamei Luo, Yang Yu, Chunxiang Zhang

Abstract readReview
In one paragraph

Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jie Gao *Department of Cardiology, The Affiliated Hospital, Southwest Medical University, No. 1, Section 1, Xianglin Road, Luzhou, Sichuan, 646000, China.
Zaiyong Zheng *Department of Cardiology, Panzhihua Central Hospital, Panzhihua, 617000, China.
Xueting YuChongqing University Jiangjin Hospital, Chongqing, 402260, China.
Yamei LuoSchool of Medical Information and Engineering, Southwest Medical University, Luzhou, Sichuan, 646000, China.
Yang YuDepartment of Cardiology, The Affiliated Hospital, Southwest Medical University, No. 1, Section 1, Xianglin Road, Luzhou, Sichuan, 646000, China. dr.yangyuself@gmail.com.
Chunxiang ZhangDepartment of Cardiology, The Affiliated Hospital, Southwest Medical University, No. 1, Section 1, Xianglin Road, Luzhou, Sichuan, 646000, China. zcxteam@163.com.ORCID 0000-0001-8303-6495

Funding

National Major Science and Technology Projects of China No. 2024ZD0537707National Natural Science Foundation of China 82030007Project of the Central Government in Guidance of Local Science and Technology Development 2024ZYD0270Research Start-up Foundation of Southwest Medical University 00040155Sichuan Science and Technology Program 25ZDYF0051
6 · The paper itself

Abstract

backgroundProtein biologics are indispensable in disease prevention, diagnosis, and therapy, yet their development remains largely constrained by reliance on native protein scaffolds, resulting in long development timelines, limited structural and functional tunability, challenges in manufacturing consistency, and high production costs. MAIN BODY: De novo protein design moves beyond the structural and functional constraints inherent to traditional approaches, enabling the direct creation of proteins with tailored structures and functions and offering a new avenue to address these challenges. In this review, we summarize the principal computational strategies underlying de novo protein design and the contribution of deep learning to its recent progress, and highlight prospective applications, major translational barriers, and the current limitations and future challenges of the field.

conclusionsDespite notable methodological progress in de novo protein design, its path toward clinical application continues to be limited by a range of biological, technical, and translational considerations. Future work will need closer coordination between computational design, experimental validation, engineering optimization, and clinical needs, with clinical feasibility considered early and refined throughout development.

Indexed as

Protein EngineeringProteinsDeep LearningHumansProteinsDeep learningDe novo protein designProtein biologicsTranslational medicine

Identifiers

PMID41639692
PMCPMC12958671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.